All News
PsA Til Death Do Us Part (1.20.2023)
Dr. Jack Cush reviews the highlights from the past week on RheumNow.com.
Read Article
AS, but not PsA, has Increased Mortality Risk
Inflammatory disorders are often accompanied by an increased mortality risk, either from secondary malignancy, infection or cardiovascular disease.
Read Article
Phase III Trials Back Bimekizumab for Spondyloarthritis
d
Medpage Today
Bimekizumab, an investigational biologic drug targeting interleukin (IL)-17A/F, appeared highly effective in patients with axial spondyloarthritis (axSpA), researchers said.
Read Article
Hydroxychloroquine Dose and Risk for Incident Retinopathy
A cohort study in Annals of Internal Medicine shows that higher hydroxychloroquine doses was associated with progressively greater risk for incident retinopathy.
Read Article
Join us! Take advantage of our early bird pricing.
https://t.co/9Up0ZgaRP2
What attendees say about our meeting:
100% found the program free of commercial bias.
99% would recommend RheumNow Live to colleagues.
95% describe the content as extremely relevant to their practice. https://t.co/HOmh0CMyyJ
Links:
Dr. John Cush RheumNow ( View Tweet)
Causes of Enthesitis: SpA (AS, reactive arthritis, PsA, enteropathic arthritis, ERA), JIA, but also in RA, leprosy, trauma, OA, DISH, acromegaly, fluorosis, retinoid therapy, hypo- or hyper-PTH, POEMS syndrome, X-linked hypophosphatemia https://t.co/pff2OWBT5C https://t.co/7zm2la4GtD
Links:
Dr. John Cush RheumNow ( View Tweet)
Tofacitinib and RA-ILD
Dr. Richard Conway discusses Abstract 2251 at ACR22 Convergence. Abstract 2251: Reduction in Rheumatoid Arthritis-Associated Interstitial Lung Disease Risk in Patients Treated with Tofacitinib
https://t.co/inndpqqbi8 https://t.co/8tRiKqT1x5
Links:
Dr. John Cush RheumNow ( View Tweet)
Ferritin may be more than biomarker in Stills, etc - may contribute directly to pathogenesis. Ferritin causes PMN activation & neutrophil extracellular traps (NETs). Could this be targeted therapeutically? https://t.co/yuvMaKqOa7 https://t.co/bjkEJvKH8d
Dr. John Cush RheumNow ( View Tweet)
Join RheumNow Live in person or virtually on 3/18 and 3/19. This meeting is unlike any other meeting you attended.
But don't take our word for it, last year's attendees say:
"Great conference. Best in the last year. I did Hopkins, CCR, and ACR too"
https://t.co/jvhKcVXNtz https://t.co/Hc6SzsPKNa
Links:
Dr. John Cush RheumNow ( View Tweet)
PsA Til Death Do Us Part
Dr. Jack Cush reviews the highlights from the past week on RheumNow
https://t.co/8km1IGdmkZ https://t.co/Drxqq1QYsC
Links:
Dr. John Cush RheumNow ( View Tweet)
Hydroxychloroquine Dose and Risk for Incident Retinopathy
A cohort study in Annals of Internal Medicine shows that higher hydroxychloroquine doses was associated with progressively greater risk for incident retinopathy.
https://t.co/DZ2UxDKgUD https://t.co/tFtNZc1Eza
Links:
Dr. John Cush RheumNow ( View Tweet)
Poorer health outcomes for at-risk patients with fractures
People at high risk of fracture are less likely to receive treatment for the underlying osteoporosis and also have poorer health outcomes.
https://t.co/XmFcnBf6US https://t.co/mgAkb0NLBv
Links:
Dr. John Cush RheumNow ( View Tweet)
Rx failures w/ nonmedical switching of biosimilars may be Nocebo effect. 140 #RA pts, 51 non-switchers & 89 switchers. Non-switchers more likely to improve than switchers (68 vs 26%, p < 0.001) and less likely to worsen (1% vs 9%, p < 0.01). https://t.co/w8lnv1V5Pi https://t.co/iT2RkkSosl
Links:
Dr. John Cush RheumNow ( View Tweet)
Naltrexone is indicated in opioid or EtOH dependence - not pain; yet it has wide off-label uses. Shown to be equal to Elavil in Rx of painful DM neuropathy; Little data from PBO RCTs in FM. Unclear how naltrexone modulates pain https://t.co/YZvfbHy9KJ https://t.co/6k9LfQSp1A
Links:
Dr. John Cush RheumNow ( View Tweet)
What RheumNow Live attendees say about our meeting:
"Great format w/shorter lectures, clinical content, good interface for audience participation to ask questions, and on-demand availability of videos post-meeting."
Join us!
https://t.co/AO0bqP5p54
@Janetbirdope @JoelKreme… https://t.co/d9ZhIbddgh
Links:
Dr. John Cush RheumNow ( View Tweet)
New Guideline: Vaccinations OK for Rheum Patients
Nearly all available vaccines can be given to people w/ rheumatologic diseases, according to a new guideline from the ACR, though the timing for their administration and dosing may need adjustment.
https://t.co/kHWyrmjkuw https://t.co/LrcFrZR2TO
Links:
Dr. John Cush RheumNow ( View Tweet)
PsART-ID study of 1216 #PsA pts showed PsA mortality to be similar to general population, but during pandemic PsA mortality doubled (5.1 vs 10.86 pandemic) with a higher increase in females (2.9 vs 8.72) than males (9.07 vs 14.73) https://t.co/AzhjOlW8vh https://t.co/YF7OlEh0sK
Links:
Dr. John Cush RheumNow ( View Tweet)
US study of 47 #GCA pts showed baseline US+ in 44/47 (72% TA, 72% LV). US was sensitivity to change over time w/ serial measures. TA-based US showed good correlation w/ Dz activity & discriminated remission vs, relapse https://t.co/2cDxac5oJw https://t.co/jH4rgvgELY
Links:
Dr. John Cush RheumNow ( View Tweet)
International survey of 394 GPs & 937 rheumatologists shows most PMR pts are not referred to Rheum. GPs referred 25% suspected PMR for Dx & 50% were returned to GP. 39% of Rheums saw new PMR >2 weeks after referral, half already on Pred https://t.co/K56nYRckpz https://t.co/j6ukqPaQXd
Links:
Dr. John Cush RheumNow ( View Tweet)
Danish registries stud of > 6 million persons finds 52898 new #IBD pts (over 18 yrs). Antibiotic exposure was assoc w/ increased risk of IBD, esp > 40 yrs. (40–60 yrs IRR 1.48; ≥60 yrs IRR 1.47) https://t.co/3P5WSjZm8M https://t.co/xHNFMWQ8dC
Links:
Dr. John Cush RheumNow ( View Tweet)